x

Posted 09 May, 2022

Longeveron Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:LGVN in a 8-K filed on 09 May, 2022.


  On May 3, 2022, Geoff Green, Chief Executive Officer of Longeveron Inc. (the "Company") provided notice to the Company and Board of Directors of his intention to step down from his position, effective June 1, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Longeveron Inc.
Health Care/Life Sciences • Biotechnology
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
Market Cap
$20.8M
View Company Details
Longeveron Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On May 3, 2022, Geoff Green, Chief Executive Officer of Longeveron Inc. (the "Company") provided notice to the Company and Board of Directors of his intention to step down from his position, effective June 1, 2022. In connection with Mr. Green's departure, the Board of Directors has unanimously appointed K. Chris Min, M.D., Ph.D., the Company's current Chief Medical Officer, to serve as interim Chief Executive Officer until such time as a permanent successor has been identified.


To further ensure a smooth transition, the Company currently intends to enter into a consulting agreement with Mr. Green, with such terms as may be mutually agreed upon, pursuant to which Mr. Green will provide consulting services to the Company for a term to be determined.